Patients with pre-existing gastrointestinal conditions, such as peptic ulcer disease or gastro-oesophageal reflux disease (GORD), should exercise particular caution
Many labs began noticing certain patterns shortly after GLP-1 therapies became widespread: patients with convincing gastrointestinal symptoms such as bloating, constipation, and gas were returning breath tests that looked delayed (rather than negative)
A 10 percent reduction in body weight is associated with a roughly 26 percent reduction in AHI (Peppard et al., JAMA , 2000)
Optic Labs supplies retatrutide for laboratory research only not for human consumption, clinical use, or any therapeutic application
Patients on the highest dose of tirzepatide (15 mg) lost around 2122.5% of their body weight over ~72 weeks [4] , whereas trials of semaglutide (Wegovy 2.4 mg) showed about 15% average weight loss in a similar period [14]